There is an uneasiness among IO players caused by $MRK success with Keytruda,  $GILD aggressive entry as IO player with Kite, 47, and Arcus, and the weak showing of CTLA-4 . Everyone wants the next checkpoint inhibitor with CRs as a monotherapy. Will $TRIL TTI-621 CD47 be it?